Lab study finds a way to weaken hard-to-treat medulloblastoma cells
Original title: CD133 structural instability as a gateway to medulloblastoma vulnerability.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done with cells in a lab dish, not in people.
The short version
In lab dishes, a drug changed a key protein on brain tumor stem cells and made those cells act less like stem cells.
What was studied. Researchers used human cell lines from Group 3 medulloblastoma, an aggressive brain tumor that is most common in children. They treated the cells in the lab with a drug called Brefeldin A, then looked at what happened to a surface protein called CD133. They also ran a computer search for already approved medicines that work in a similar way.
What they found. The drug disrupted the structure of CD133 and the tumor stem cells lost some of their stem-like traits. Those cells were less able to grow new colonies, a growth signal pathway inside them was turned down, and they communicated with each other less. The computer search turned up medicines already approved for use in patients that had similar effects on the cells.
What this means, and what it doesn't
What it could mean: This suggests a possible new way to go after the tumor cells that resist standard treatment. Because some of the medicines found are already approved, researchers may be able to test the idea sooner than with a brand new drug.
What it doesn't mean: This work was done only in cells in a lab dish. It was not tested in animals and not in people. No one knows yet if it would shrink a tumor or help someone live longer. It is not something a doctor can offer you, and it is not a cure.
Source: PubMed, July 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.